Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Drug-Related Side Effects and Adverse Reactions 2Breast Neoplasms 2Sarcoma, Alveolar Soft Part 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Cancer Related Fatigue 1Breast Neoplasms, Male 1

Interventions

Paclitaxel 37Carboplatin 28pembrolizumab 19Surveys and Questionnaires 11temsirolimus 10Radiotherapy 10Cisplatin 10Doxorubicin 9Bevacizumab 9lenvatinib 8Docetaxel 8Nivolumab 7Metformin 7Gemcitabine 7Early Intervention, Educational 7Counseling 7Sirolimus 6Radiation 6Megestrol Acetate 6Indocyanine Green 6olaparib 5Topotecan 5Therapeutics 5Psychiatric Rehabilitation 5Methods 5Letrozole 5Ipilimumab 5Chemotherapy, Adjuvant 5ridaforolimus 4Trastuzumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Endometrial Neoplasms × Pyridoxine × Clear all
NCT00245050 2011-12-30

Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer

Case Comprehensive Cancer Center

Phase 3 Completed
34 enrolled 9 charts
BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Breast Neoplasms, Male, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡